Merck is acquiring Cidara Therapeutics to diversify its pipeline with CD388, a late-phase, breakthrough-designation antiviral agent for influenza prevention in high-risk populations.

Ascletis Pharma has announced the co-formulation and planned clinical development of ASC36, a once-monthly next-generation amylin receptor agonist, and ASC35, a once-monthly next-generation GLP-1/GIPR dual agonist, targeting significant advancements in peptide therapeutics manufacturing and metabolic disease treatment in Asia.

Teva’s Q3 2025 results show a 2% revenue drop in Europe, offset by innovation-driven R&D expansion and strategic product launches.

Vietnam's Ministry of Health grants three-year market licence to Russian-made pembrolizumab drug and 13 other vaccines and biologics, reinforcing regulatory rigor and supply protocols in the oncology sector.

Evotec has secured a $5 million milestone from Bristol Myers Squibb after the FDA accepted an IND for their jointly-developed molecular glue degrader, marking progress in their protein degradation R&D alliance.

Dr Richard Pazdur, an expert in oncology regulation, is the new leader of the FDA’s Center for Drug Evaluation and Research (CDER), signaling intensified regulatory reforms and accelerated drug approvals in the US pharmaceutical sector.

Shilpa Pharma Lifesciences, a leading Indian CDMO, secures EcoVadis Gold Medal for exemplary sustainability, bolstering its global B2B reputation.

Cosmo Pharmaceuticals secures a higher S&P Global ESG rating and EcoVadis Bronze Medal for its Italian manufacturing plant, advancing transparency and supplier sustainability across its European pharma operations.

Pharmaceutical manufacturers are calling for the FDA to extend its PreCheck program to existing facilities to accelerate domestic production and address drug shortages.

Venus Remedies has obtained new marketing authorisations for Methotrexate, Cefuroxime, and Irinotecan in Vietnam, expanding its critical care exports in Southeast Asia.